Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2032-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 trial using indoximod, an inhibitor of the immune "checkpoint" pathway
indoleamine 2,3-dioxygenase (IDO), in combination with Tergenpumatucel-L immunotherapy and
Docetaxel to treat subjects with advanced Non-Small Cell Lung Cancer (NSCLC). From a
practical standpoint, a successful tumor immunotherapy will likely require a combination
treatment with additional therapeutic interventions that both activate an immune response and
remove redundant mechanisms of tolerance maintenance. This clinical trial utilizes the
combination of the chemotherapeutic agent, docetaxel, plus two investigational methods of
cancer immunotherapy: the first, tergenpumatucel-L, is intended to educate the human immune
system to recognize the abnormal components found in lung cancer cells, resulting in an
immune response intended to destroy or block the growth of the cancer; and the second, the
IDO inhibitor Indoximod, will overcome tumor-induced immune suppression.
The goal of this study is to assess the progression-free survival (PFS) and overall survival
(OS) rates in this patient population. This study will provide a foundation for future trials
testing indoximod combined with tergenpumatucel-L.